In part one of this four-part series we talk about examples of wrong entry into stocks with rich valuations and how to avoid them
The second of this four-part series will talk about how you can lose wealth when you entry timing goes wrong in cyclical businesses.
The third of this four-part series talks about how every bull market hides low quality businesses and how you can stay clear of such companies.
In this final part of this four-part series we discuss how many promising turnaround stories never say the light of day in the stock market and also talk about the perils of placing too much faith in dividend earners that show no potential for growth.
SIPs in stocks have caught up in the last few years after many online broking platforms started offering this as an automated feature. But is
The Nifty 50 has scaled new highs, displaying strength over the past few months. Is the rally in the Nifty 50 over or can it continue?
For shareholders of HDFC, should you continue holding the stock post its merger with HDFC Bank?
Building a stock portfolio is not easy, but it’s not terribly hard either. Aarati Krishnan gives useful pointers in this QA article on building a stock portfolio.
When a company, especially an MNC, discloses little by way of scheduled earnings calls or business information, save for its AGM, its stock price can also react only to earnings or move on visibility in prospects of the company. We took that risk in one such company which is in the business of automation, in late 2021.
With consumer companies having pulled through a period of demand slump, the worst appears to be behind. Signs of a recovery in rural demand can help broad-base the overall consumption improvement. This consumer company gets a strong foundation in its household brand names. But it has been evolving from building up its own health and […]
The demerger of Piramal Enterprises (PEL) was a long awaited one in the market. With sizable businesses in both financial services and pharmaceuticals, the demerger
Pharma companies in the API (Active Pharmaceutical Ingredient) space in India have struggled in the past couple of years, confronted by rising input costs, poor price realization and competition from China even while remaining dependent on China for inputs. All these also impact the even-otherwise modest margins.
Some of these challenges appear to be abating, providing an opportunity to pick select API players in the pharma space.
Hold On
You are being redirected to another page,
Elevate Your Wealth with Professional Portfolio Management
